Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617 | Director | April 04, 2025 | April 08, 2025 |
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | Director | May 19, 2017 | May 24, 2017 |
| IMMUNOMEDICS INCIMMU · Entity 145732 | Director | January 08, 2017 | January 10, 2017 |
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director | June 04, 2026 | June 05, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 05, 2026 | June 12, 2026 |
| MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770 | 10% owner · See Explanation of Responses | July 16, 2019 | July 18, 2019 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director | May 15, 2017 | May 17, 2017 |
| Orchestra BioMed Holdings, Inc.OBIO · Entity 434 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anebulo Pharmaceuticals, Inc.
Report date April 04, 2025 · Filed April 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 25,000 |
Reported balance
After 2025-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-04 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 4,964 |
Reported balance
After 2025-04-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-04 · Grant · Acquired 4,964 · Balance 4,964 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders.
Aralez Pharmaceuticals Inc.
Report date May 19, 2017 · Filed May 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | IndirectBy JALAA Equities, LP | 337,644 |
Reported balance
After 2017-05-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-05-19 · Sale · Disposed 51,041 · Balance 337,644 F1: This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Includes 45,469 shares issued in connection with a previously exercised warrant. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. |
| Common Shares, without par valueSEC Table I · non-derivative | IndirectBy JALAA Equities, LP | 104,176 |
Reported balance
After 2017-05-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-05-22 · Sale · Disposed 233,468 · Balance 104,176 F4: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. |
| Common Shares, without par valueSEC Table I · non-derivative | IndirectBy JALAA Equities, LP | 0 |
Reported balance
After 2017-05-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-05-23 · Sale · Disposed 104,176 · Balance 0 F5: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. |
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2017-05-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 15,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Includes 45,469 shares issued in connection with a previously exercised warrant.
F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.
F4: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
IMMUNOMEDICS INC
Report date January 08, 2017 · Filed January 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2024-01-08 | Direct | 22,500 |
Reported balance
After 2017-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-08 · Grant · Acquired 22,500 · Balance 22,500 |
LIFECORE BIOMEDICAL, INC. \DE\
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,967 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 25,907 · Balance 69,967 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
LIGAND PHARMACEUTICALS INC
Report date June 05, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,580 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 836 · Balance 107,580 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. F2: The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records. |
| Common StockSEC Table I · non-derivative | Direct | 107,080 |
Reported balance
After 2026-06-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-10 · Sale · Disposed 500 · Balance 107,080 |
| Common StockSEC Table I · non-derivative | Direct | 102,580 |
Reported balance
After 2026-06-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-06-11 · Sale · Disposed 4,500 · Balance 102,580 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.00 · Expires 2036-06-05 | Direct | 2,938 |
Reported balance
After 2026-06-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-05 · Grant · Acquired 2,938 · Balance 2,938 F4: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectIndirect | 13,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 13,000 F3: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records.
F3: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
F4: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
MERRIMACK PHARMACEUTICALS INC
Report date July 16, 2019 · Filed July 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,802 |
Reported balance
After 2019-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-07-16 · Purchase · Acquired 302 · Balance 3,802 F1: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
NOVELION THERAPEUTICS INC.
Report date May 15, 2017 · Filed May 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 242,433 |
Reported balance
After 2017-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-05-15 · Purchase · Acquired 361 · Balance 242,433 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. |
| Common SharesSEC Table I · non-derivative | IndirectBy JALAA Equities, L.P. | 127,491 |
Reported balance
Holding disclosure · report date 2017-05-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 127,491 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. |
| Common SharesSEC Table I · non-derivative | IndirectBy JLV Investments, LP | 6,256 |
Reported balance
Holding disclosure · report date 2017-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,256 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. |
| Common SharesSEC Table I · non-derivative | IndirectBy JLD Investments, L.P. | 16,553 |
Reported balance
Holding disclosure · report date 2017-05-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 16,553 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest.
Orchestra BioMed Holdings, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2036-06-23 | Direct | 42,553 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 42,553 · Balance 42,553 F1: The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 29, 2016 Filed Dec 1, 2016 16:06 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantCommon Shares, without par value | 1,136,363 | $1.76 | $1,999,998.88 |
DisclosureSEC source: 0001104659-16-160115 · a4.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,210,363 Read SEC document |
| November 25, 2016 Filed Nov 25, 2016 22:58 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,478 | $106.96 | $372,006.88 |
DisclosureSEC source: 0000886163-16-000249 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 185,898 F1 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| November 22, 2016 Filed Nov 25, 2016 22:58 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 15,001 | $107.40 | $1,611,065.40 |
DisclosureSEC source: 0000886163-16-000249 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 189,376 F1 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| November 18, 2016 Filed Nov 18, 2016 21:48 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,000 | $105.00 | $525,000.00 |
DisclosureSEC source: 0000886163-16-000247 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 204,377 F1 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:48 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,330 | $106.33 | $141,418.90 |
DisclosureSEC source: 0000886163-16-000247 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 209,377 F1 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| September 16, 2016 Filed Apr 25, 2017 20:30 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | PurchaseCommon Shares, without par value | 295,929 | $5.86 | $1,732,664.30 |
DisclosureSEC source: 0001104659-17-025903 · a4.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JALAA Equities, LP Disclosed balance after: 343,216 F1 · ownership.nature: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.